We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari fo... Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. Show more
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday...
โ Study Met Primary Endpoint Demonstrating Clinically Significant Additive Reductions in Ambulatory Systolic Blood Pressure of Up to 12.1 mmHg Across Three Independent Study Cohorts at Month 3 โ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of...
โ Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health โ โ Genealogist and Health Educator Bernice...
- Die Studie erreichte den primรคren Endpunkt und zeigte eine klinisch signifikante Senkung des systolischen Blutdrucks im dritten Monat, wenn Zilebesiran zu einem Diuretikum, einem...
โ Lโรฉtude a atteint le critรจre dโรฉvaluation principal dรฉmontrant une rรฉduction cliniquement significative de la pression artรฉrielle systolique au 3e mois lorsque le zilebesiran est ajoutรฉ ร un...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -6.64 | -4.37417654809 | 151.8 | 151.8 | 144.23 | 452040 | 146.63714786 | CS |
4 | -1.49 | -1.01602454824 | 146.65 | 159.34 | 143.66 | 531552 | 150.86159987 | CS |
12 | -38.93 | -21.1472649248 | 184.09 | 184.455 | 143.52 | 882029 | 155.83337643 | CS |
26 | -20.14 | -12.183908046 | 165.3 | 199.38 | 143.52 | 722238 | 164.17354284 | CS |
52 | -56.06 | -27.8600536726 | 201.22 | 218.88 | 143.52 | 662038 | 176.27733391 | CS |
156 | 4.6 | 3.27262379055 | 140.56 | 242.97 | 117.58 | 752973 | 180.10455483 | CS |
260 | 63.71 | 78.2197667281 | 81.45 | 242.97 | 65.81 | 728948 | 155.32237629 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions